Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
Walter Reinisch(Medical University of Vienna), Tim Wyant(Curis (United States)), Themistocles Dassopoulos(Cedars-Sinai Medical Center), Rebecca Curtis(Takeda (United States)), James D. Lewis(University of Pennsylvania), Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), Arne Røseth(Lovisenberg Diakonale Høgskole), Brian Bressler(University of British Columbia), Jing Xu(Kunming Medical University), Maria Rosario(Millennium Engineering and Integration (United States)), Asit Parikh, Philip Ginsburg(Quinnipiac University), Huyuan Yang(Takeda (United States)), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 40
Related Papers
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
|Nature Medicine|2013|4.4k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k